Effects of estrogens and hormone replacement therapy on breast cancer risk and on efficacy of breast cancer therapies

Maturitas

Volumn 36, Issue 1, 2000, Pages 1-17

  Verheul, H A M ^a   Coelingh Bennink, H J T ^a   Kenemans, P ^b   Atsma, W J ^a   Burger, C W ^c   Eden, J A ^d   Hammar, M ^e   Marsden, J ^f   Purdie, D W ^g  

^a NV ORGANON   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d ROYAL HOSPITAL FOR WOMEN   (Australia)

^e LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^f MAYDAY UNIVERSITY HOSPITAL   (United Kingdom)

^g HULL ROYAL INFIRMARY   (United Kingdom)

Author keywords

Breast cancer; Estrogens; Hormone replacement therapy

Indexed keywords

CYCLOPHOSPHAMIDE; ESTRADIOL; ESTRIOL; ESTROGEN; ESTROGEN RECEPTOR; FLUOROURACIL; GESTAGEN; LEVONORGESTREL; METHOTREXATE; NANDROLONE; ORAL CONTRACEPTIVE AGENT; TAMOXIFEN;

BREAST CANCER; CANCER HORMONE THERAPY; CANCER INCIDENCE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; ESTROGEN BLOOD LEVEL; HORMONAL REGULATION; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; HUMAN TISSUE; META ANALYSIS; PROGNOSIS; REVIEW;

EID: 0034738373     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(00)00150-X     Document Type: Article

References (105)

1. Baum U. Sex steroids and malignancies. Osteoporosis Int. 1(1):1997;S18-S22.
2. Lupulescu A. Estrogen use and cancer incidence: a review. Cancer Invest. 13:1995;287-295.
3. Arpels J.C., Nachtigall R.D. Gonadal hormones and breast cancer risk: the estrogen window hypothesis revisited. Menopause. 1:1994;49-55.
4. Ciocca D.R., Fanelli M.A. Estrogen receptors and cell proliferation and breast cancer. TEM. 8:1997;313-321.
5. Schneider H.P.G., Jackisch C. Potential benefits of estrogens and progestagens on breast cancer. Int. J. Fertil. 43:1998;278-285.
6. Kloosterboer H.J., Schoonen W.G.E.J., Deckers G.H., Klijn J.G.M. Effects of progestagens and Org OD14 in in vitro and in vivo tumor models. J. Steroid Biochem. Mol. Biol. 49:1994;311-318.
7. Garcia M., Derocq D., Freiss G., Rochefort H. Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. Proc. Natl. Acad. Sci. 89:1992;11538-11542.
8. Garcia M., Derocq D., Platet N., Bonnet S., Brouillet J.P., Touitou I., Rochefort H. Both estradiol and tamoxifen decrease proliferation and invasiveness of cancer cells transfected with a mutated estrogen receptor. J Steroid Biochem. Mol. Biol. 61:1997;11-17.
9. Klauber N., Parangi S., Flynn E., Hamel E., Damato R.J. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. 57:1997;81-86.
10. Rochefort H., Platet D., Hayashido Y., Derocq D., Lucas A., Cunat S., Garcia M. Estrogen receptor mediated inhibition of cancer cell invasion and motility: an overview. J. Steroid Biochem. Mol. Biol. 65:1998;163-168.
11. Brunner N., Bronzert D., Vindelov L.L., Rygaard K., Sprang-Thomson E., Lippman M.E. Effect on growth and cell cycle kinetics of estradiol and tamoxifen on MCF-7 human breast cancer cells grown in vitro and in nude mice. Cancer Res. 49:1989;1515-1520.
12. McGuire W.L. Hormone receptors in breast cancer. Bullbrook R.D. Cancer Surveys. 5:1986;Oxford University Press, Oxford.
13. DiSaia P.J. Hormone replacement therapy for breast cancer survivors: facts versus fears. Int. Urogynecol. 6:1995;125-159.
14. Disaia P.J., Grosen E.A., Kurosaki T., Gildea M., Cowan B., Anton-Culver H. Hormone replacement therapy in breast cancer survivors: a cohort study. Am. J. Obstet. Gynecol. 17:1996;1494-1499.
15. DiSaia P.J. Estrogen replacement therapy for the breast cancer survivor: a reappraisal. J. Surg. Oncol. 64:1997;175-180.
16. Eden A., Bush T., Nand S., Wren B.G. A case-control study of combined continuous estrogen-progestin replacement therapy among women with a personal history of breast cancer. J. North Am. Menopause Soc. 2:1995;67-72.
17. Cobleigh M.A., Berris R.F., Bush T., Davidson N.E, . Robert N.J., Sparano J.A., Tormey D.C., Wood W.C. Estrogen replacement therapy in breast cancer survivors; a time for change. J. Am. Med. Assoc. 272:1994;540-545.
18. Marsden J., Baum M., Sacks N.P.M. Hormone replacement therapy in women with previous breast cancer. TEM. 9:1998;32-38.
19. Kenemans P., Scheele P., Burger C.W. Hormone replacement therapy and breast cancer morbidity, mortality and recurrence. Eur. J. Obstet. Gynecol. Reprod. Biol. 71:1997;199-203.
20. Bergkvist L., Persson I. Hormone replacement therapy and breast cancer: a review of current knowledge. Drug Safety. 5:1996;360-370.
21. Roy J.A., Sawka C.A., Protchard K.I. Hormone replacement therapy in women with breast cancer: do the risks outweigh the benefits? J. Clin. Oncol. 14:1996;997-1006.
22. Vassilopoulou-Sellin R., Theriault R., Klein M.J. Estrogen replacement therapy in women with prior diagnosis and treatment of breast cancer. Gynecol. Oncol. 65:1997;89-93.
23. Thomas H.V., Key T.J., Allen D.S., Moore J.W., Dowsett M., Fentiman I.S., Wang D.Y. A prospective study of endogenous serum hormone concentrations and breast cancer risk in postmenopausal women on the island of Guernsey. Brit. J. Cancer. 76:1997;401-405.
24. Tonolio P.G., Levitz Z., Zeleniuch-Jacquotte A., Banerjee S., Koenig K.L., Shore R.E., Strax P., Pasternak B.S. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J. Natl. Cancer Inst. 87:1995;190-197.
25. Berrino F., Muti P., Micheli A., Bolelli G., Krogh V., Sciajno R., Pisani P., Panico S., Secreto G. Serum sex hormone levels after menopause and subsequent breast cancer. JNCI. 88:1996;291-296.
26. Cauley J.A., Lucas F.L., Kuller L.H., Stone K., Browner W., Cummings S.R. et al. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Ann. Intern. Med. 130:1999;270-277.
27. Dorgan J.F., Loncope C., Stephenson H.E. Jr, Falk R.T., Miller R., Franz C. et al. Relation of prediagnostic serum estrogen and androgen levels and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 5:1996;533-539.
28. Hankinson S.E., Willett W.C., Manson J.E., Colditz G.A., Hunter D.J., Spiegelman D., Barbieri R.L., Speizer F.E. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J. Natl. Cancer Inst. 90:1998;1292-1299.
29. Pasqualini J.R., Chetrite G., Blacker C., Feinstein M.C., Delalonde L., Talbi M., Maloche C. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. J. Clin. Endocrinol. Metab. 81:1996;1460-1464.
30. Purohit A., Wang D.Y., Ghilchik M.W., Reed M.J. Regulation of aromatase and sulphatase in breast tumour cells. J. Endocrinol. 150:1996;S65-S71.
31. Santen R.J., Santner S.J., Pauley R.J., Tait L., Kaseta J., Demers L.M., Hamilton C., Yue W., Wang J.P. Estrogen production via the aromatase enzyme in breast carcinoma: which cell type is responsible? J. Steroid Biochem. Mol. Biol. 61:1997;267-271.
32. Parazzini F., Braga C., LaVecchia C., Negri E., Acerboni S., Franceschi S. Hysterectomy, oophorectomy in premenopause and risk of breast cancer. Obstet. Gynecol. 90:1997;453-456.
33. Locker G.Y. Hormonal therapy of breast cancer. Cancer Treat. Rev. 24:1998;221-240.
34. Longnecker M.P., Bernstein L., Paganini-Hill A., Enger S.M., Ross R.K. Risk factors for in situ breast cancer. Cancer Epiderml. Biomarkers Prev. 5:1996;961-965.
35. Marsden J, Sacks N.P.M. Hormone replacement therapy and breast cancer. Endocr related Cancer. 3:1996;81-97.
36. Lambe M., Hsieh C.C., Trichopoulos D. et al. Transient increase in the risk of breast cancer after giving birth. New Eng. J. Med. 331:1994;509.
37. Schoulz E. von, Johansson H., Wilking N., Rutqvist L.E. Influence of prior and subsequent pregnancy on breast cancer prognosis. J. Clin. Oncol. 13:1995;430-434.
38. Guinee V.F., Olsson H., Moller T., Hess K.R., Taylor S.H., Fahey T. et al. Effect of pregnancy on prognosis for young women with breast cancer. Lancet. 343:1994;1587-1589.
39. Russo J., Russo I. The etiopathogenesis of breast cancer prevention. Cancer Lett. 90:1995;81-89.
40. Beral V. Collaborative group on hormonal factors in breast cancer: Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet. 347:1996;1713-1727.
41. Rosner D., Lane W. Oral contraceptive use has no adverse effect on the prognosis of breast cancer. Cancer. 57:1986;591-596.
42. Vessey M., Baron J., Doll R. et al. Oral contraceptives and breast cancer: final report of an epidemiological study. Br. J. Cancer. 47:1983;455-475.
43. Nachtigall L.E., Nachtigall R.H., Nachtigall R.D., Beckman E.M. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet. Gynecol. 54:1979;749.
44. Nachtigall M.J., Smilen S.W., Nachtigall R.D., Nachtigall R.H., Nachtigall L.E. Incidence of breast cancer in a 22 year study of women receiving estrogen replacement therapy. Obstet. Gynecol. 80:1992;827-830.
45. Beral V. Collaborative group on hormonal factors in breast cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet. 350:1997;1047-1059.
46. Cobleigh M.A., Norlock F.E., Oleske D.M., Starr A. Hormone replacement therapy and high S phase in breast cancer. J. Am. Med. Assoc. 281:1999;1528-1530.
47. Bilimoria M.M., Winchester D.J., Sener S.F., Motykie G., Sehgal U.L., Winchester D.P. Estrogen replacement therapy and breast cancer: Analysis of age of onset and tumor characteristics. Ann. Surg. Oncol. 6:1999;200-207.
48. Dupont W.D., Page D.L., Parl F.F., Plummer W.D., Schuyler P.A., Kasami M., Jensen R.A. Estrogen replacement therapy in women with a history of proliferative breast disease. Cancer. 85:1999;1277-1283.
49. Colditz G.A., Hankinson S.E., Hunter D.J., Willet W., Manson J.E., Stampfer M.J., Hennekens C.H., Rosner B., Speizer F.E. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N. Eng. J. Med. 332:1995;1589-1593.
50. Ettinger B., Friedman G.D., Budh T., Quesenberg C.P. Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet. Gynecol. 87:1996;6-12.
51. Grodstein F., Stampfer M.J., Colditz G.A. et al. Postmenopausal hormone therapy and mortality. New Eng. J. Med. 336:1997;1769-1775.
52. Schairer C., Gail M., Byrne C., Rosenberg P.S., Sturgeon S.R., Brinton L.A., Hoover R.N. Estrogen replacement therapy and breast cancer survival in a large screening study. J. Natl Cancer Inst. 91:1999;264-270.
53. Bergkvist L., Adami H.O., Persson I., Bergstrom R., Krusema U.B. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am. J. Epidmiol. 130:1989;221-228.
54. Persson I., Yuen J., Bergkvist L., Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy; long-term follow-up of a Swedish cohort. Int. J. Cancer. 67:1996;327-332.
55. Schairer C., Adami H.O., Hoover R., Persson I. Cause-specific mortality in women receiving hormone replacement therapy. Epidemiology. 8:1997;59-65.
56. Gambrell R.D. Sex steroids and cancer. Obstet. Gynecol. Clin. North Am. 14:1987;191-206.
57. Gambrell R.D. Breast cancer: Improved prognosis in hormone users and decreased incidence in oestrogen-progestagen users. Mann R.D. Hormone Replacement Therapy and Breast Cancer Risk. 1992;133-145 The Parthenon Publishing Group, Carnforth.
58. Hunt K., Vessey M., McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Brit. J. Obstet. Gynaecol. 97:1990;1080-1086.
59. Vessey M.P., Hunt K., MacPherson K. Hormone replacement therapy and breast cancer: overview of the university of Oxford studies. Mann R.D. Hormone Replacement Therapy and Breast Cancer Risk. 1992;185 The Parthenon Publishing Group, Carnforth.
60. Henderson B.E., Paganini-Hill A., Ross R. Decreased mortality in users of estrogen replacement therapy. Arch. Intern. Med. 151:1991;75-78.
61. Criqui M.H., Suarez L., Barrett-Connor E., McPhillips J., Wingard D.L., Garland C. Postmenopausal estrogen use and mortality. Am. J. Epidemiol. 128:1988;606-614.
62. Folsom A.R., Mink P.J., Sellers T.A., Hong C.P., Zheng W., Potter J.D. Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am. J. Pub. Health. 85:1995;1128-1132.
63. Willis D.B., Calle E.E., Miracle-McMahill H.L., Heath C.W. Estrogen replacement therapy and the risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control. 7:1996;449-457.
64. Harding C, Knox WF, Faragher EB, Baildam A, Bundred. Hormone replacement therapy and tumour grade in breast cancer: prospective study in screening unit. Brit Med J 1996;312:1646-1647.
65. Magnusson C., Holmberg L., Norden T., Lindgren A., Persson I. Prognostic characteristics in breast cancers after hormone replacement therapy. Breast Cancer Res. Treat. 38:1996;325-334.
66. Holli K., Isola J., Cuzick J. Hormone replacement therapy and biological aggressiveness of breast cancer. Lancet. 350:1997;1704-1705.
67. Willis D.B. Does estrogen replacement therapy reduce the risk of fatal breast cancer in postmenopausal women? Maturitas. 27:1997;105-108.
68. O'Connor I.F., Shembekar M.V., Shousha S. Breast carcinoma developing in patients on hormone replacement therapy: a histological and immunohistological study. J. Clin. Pathol. 51:1998;935-938.
69. Capstur S.M., Morrow M., Sellers T.A. Hormone replacement therapy and risk of breast cancer with a favourable histology: results of the Iowa Women's Health Study. J. Am. Med. Assoc. 281:1999;2091-2097.
70. Stoll B.A. Hormone replacement therapy in women treated for breast cancer. Eur. J. Cancer Clin. Oncol. 25:1989;1909-1913.
71. Wile A.G., Opfell R.W., Margiketh D.A. Hormone replacement therapy in previously treated breast cancer patients. Am. J. Surg. 165:1993;372-375.
72. DiSaia P.J., Odicino F., Rosen E.A., Cowan B., Pecorelli S., Wile A.G. Hormone replacement therapy in breast cancer. Lancet. 342:1993;1232. letter.
73. Powles T.J., Hickish T., Casey S., O'Brien M. Hormone replacement after breast cancer. Lancet. 341:1993;60-61.
74. Eden A, Wren B, Dew J. Hormone replacement therapy after breast cancer. In: Glode LM, Friedman MA, Ramsay NK, Wood WC, Berek JS, Blayney DW et al. (Eds). Educational book. Philadelphia: American Society of Clinical Oncology, 1996:187-189.
75. Dew J., Eden J., Beller E., Magarey C., Schwartz P., Crea P., Wren B. A cohort study of hormone replacement therapy given to women previously treated for breast cancer. Climacteric. 1:1998;137-142.
76. Beckmann M.W., Mohrmann T., Kuschel B., Dadze A., Mohrmann S., Dall P. et al. Hormone replacement therapy (HRT) after breast cancer treatment: results from an observational study. Geburtsh u Frauenheilk. 58:1998;193-196.
77. Guidozzi F. Estrogen replacement therapy in breast cancer survivors. Int. J. Gynecol. Obstet. 64:1999;59-63.
78. Ursic-Vrscaj M., Bebar S. A case-control study of hormone replacement therapy after primary surgical breast cancer treatment. Eur. J. Surg. Oncol. 25:1999;146-151.
79. Peters G.N., Jones S.E. Estrogen replacement therapy in breast cancer patients; a time for a change? Proc. Am. Soc. Clin. Oncol. A148:1996;121.
80. Decker D.A., Pettinga J.E., Cox T.C., Burdakin J.H., Jaiyesimi I.A., Benitez P.R. Hormone replacement therapy in breast cancer survivors. Breast J. 3:1997;63-68.
81. Bluming A.Z., Wile A.G., Schain W., Waisman J.R., Dosik G.M., Olsen G.A. et al. Hormone replacement therapy in women with previously treated primary breast cancer: update II. Proc. Ann. Meet. Am. Soc. Clin. Oncol. 15(A203):1997;134.
82. Dhodapkar M.V., Ingle J.N., Ahmann D.L. Estrogen replacement therapy withdrawal and regression of metastatic breast cancer. Cancer. 75:1995;43-46.
83. Ross R.K., Paganini-Hill A., Wan P.C., Pike M.C. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J. Natl. Cancer Inst. 4:2000;328-332.
84. Sands R., Studd J. Hormone replacement therapy for women after breast carcinoma. Curr. Opinion Obstet. Gynaecol. 8:1996;216-220.
85. Pearlstone D.B., Pearlstone M.M., Vassilopoulou-Sellin R., Singletary S.E. Hormone replacement therapy and breast cancer. Ann. Surg. Oncol. 6:1999;208-217.
86. Gompel A, Kandouz M, Lombet A, Perrot J-Y, DeChambine S, Siromachkova M, Rostne W, Poitout Ph. Hormonal regulation of apoptosis in breast cancer. Abstract presented at FIGO, Copenhagen, 1997.
87. Gompel A, Kandouz M, Perrot J-Y, Lombet A, DeChambine S, Thövenin D, Mimoun M, Rostbne W, Poitout Ph. Hormonal regulation of apoptosis in normal breast cells. Abstract presented at FIGO, Copenhagen, 1997.
88. Kandouz M, Schimmel K, Jacob D, Siromachkova M, Verloop S, Mimoun M, Therwath A, Gompel A, Poitout Ph. Hormonal regulation of BCL-2 protein family in breast cells. Abstract presented at FIGO, Copenhagen, 1997.
89. Chetrite G., Kloosterboer H.J., Pasqualini J.R. Effect of tibolone (Org OD14) and its metabolites on estrone sulfatase activity in MCF-7 and T47D mammary cancer cells. Anticancer Res. 17:1997;135-140.
90. Pasqualini J.R., Paris J., Sitruk-Ware R., Chetrite G., Botella J. Progestins and breast cancer. J. Steroid Biochem. Mol. Biol. 65:1998;225-235.
91. Peltoketo H, Vihko P, Vihko R. Regulation of estrogen action: role of 17-beta hydroxysteroid dehydrogenases. In: Lidwick G (Ed.). Vitamins and Hormones. Advances in research and applications. Academic Press, 1999 volume 55 page 353-398.
92. Gompel A, Kandouz M, Jacob D, Siromachkova M, Thvenin D, Mimoun M, Therwath A, Poitout Ph. OD14 (Livial®) actions on normal breast cells. Abstract presented at FIGO, Copenhagen, 1997.
93. Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on the risk of breast cancer in Denmark. Int. J. Cancer. 42:1988;832-838.
94. Cline J.M., Soderqvist G., von Schoultz E., Skoog L., von Schoultz B. Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. Am. J. Obstet. Gynecol. 174:1996;93-100.
95. Plu-Bureau G., Le M.G., Sitruk-Ware R., Thalabard J.C., Mauvais-Jarvis P. Progestogen use and decreased risk of breast cancer in a cohort study of premenopausal women with benign breast disease. Br. J. Cancer. 70:1994;270-277.
96. ACOG Committee Opinion: Committee on gynecologic practice. Estrogen replacement therapy in women with previously treated breast cancer. Int J Gynecol Obstet 1994;45:184-188.
97. Bonadonna G., Valagussa P., Moliterni A., Zambetti M., Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node positive breast cancer: results of 20 years follow-up. New Eng. J. Med. 14:1995;901-906.
98. Pritchard K.I. Ovarian ablation as adjuvant therapy for early-stage breast cancer. Cancer Treat. Res. 94:1998;158-180.
99. Loprizini C.L., Peethambaram P. Management of menopausal symptoms in breast cancer patients. Ann. Med. 27:1997;653-656.
100. Fisher B., Constantino J., Redmond C. et al. A randomised clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor positive tumours. New Eng. J. Med. 320:1989;479-484.
101. Jordan V.C., Fritz N.F., Langan-Fahey S., Thompson M., Tormey D.C. Alterations of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. J. Natl. Cancer Inst. 83:1991;1488.
102. Yasumura T., Akami T., Mitsou M., Oka T., Naitoh K., Yamamoto T., Honjyo H., Okada H. The effect of adjuvant therapy with or without tamoxifen on the endocrine function of patients with breast cancer. Jpn. J. Surg. 20:1990;369-375.
103. Goodman Gilman A, Rall TW, Nies AS, Taylor P. The pharmacological basis of therapeutics, 8th edition, 1990. Pergamon Press pp. 1256-1257.
104. Pagani O., O'Neill A., Castiglione M., Gelber R.D., Goldhirsch A., Rudenstam C.-M. et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the international breast cancer study group (IBCSG) trial V1. Eur. J. Cancer. 34:1998;632-640.
105. Horn Y., Walach N., Pavlotsky A., Barak F., Benz C. Randomised study comparing chemotherapy with and without estrogen priming in advanced breast cancer. Int. J. Oncol. 4:1994;499-501.